Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

100.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Via ACCESSWIRE
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Via ACCESSWIRE
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in 8/17 Morning Trading
Via Investor Brand Network
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
Via ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
Via ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
Via ACCESSWIRE
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
From Merck & Co., Inc.
Via Business Wire
Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
Via ACCESSWIRE
Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in June 2023
Via ACCESSWIRE
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
Via ACCESSWIRE
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
Exposures COVID-19 Economy
InvestorNewsBreaks – Cisco Systems Inc. (NASDAQ: CSCO) Featured in Yahoo! Finance Article
Via Investor Brand Network
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
Via ACCESSWIRE
Moderna: Declining Performance And Relative Weakness
Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Via ACCESSWIRE
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Via ACCESSWIRE
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
Exposures COVID-19
3 Underperforming Nasdaq 100 Stocks Worth a Closer Look
Given the volatility and growth potential associated with the Nasdaq’s elite, investors may want to keep these recent underperformers on the watch list. 
Via MarketBeat
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.